Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongwha Pharm Co., Ltd. (000020:KRX), powered by AI.
Dongwha Pharm Co., Ltd. is currently trading at ₩5,330. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Dongwha Pharm Co., Ltd. on Alpha Lenz.
Dongwha Pharm Co., Ltd.'s P/E ratio is 17.1.
“Dongwha Pharm Co., Ltd. trades at a P/E of 17.1 (fair value) with modest ROE of 2.3%. 3Y revenue CAGR of 13.4% highlights clear growth momentum.”
Ask for details →Dongwha Pharm Co., Ltd. is a pharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of medicinal products. Established in South Korea, the company has a rich history and is known for its contributions to the healthcare industry. Dongwha Pharm's product portfolio includes over-the-counter drugs, prescription medications, health supplements, and healthcare products. The company operates within both domestic and international markets, offering a broad range of pharmaceuticals that cater to diverse medical needs. Dongwha Pharm Co., Ltd. places a strong emphasis on innovation and quality, investing significantly in research and development to ensure the effectiveness and safety of its products. It serves a wide array of therapeutic areas including cardiovascular, gastrointestinal, and respiratory health, among others. As a key player in the South Korean pharmaceutical industry, Dongwha Pharm contributes to public health advancements and economic vitality through its expansive product line and commitment to scientific research. The company actively participates in the global pharmaceutical supply chain, maintaining partnerships and collaborations that enhance its competitive position in the market.
“Dongwha Pharm Co., Ltd. trades at a P/E of 17.1 (fair value) with modest ROE of 2.3%. 3Y revenue CAGR of 13.4% highlights clear growth momentum.”
Ask for details →Dongwha Pharm Co., Ltd. (ticker: 000020) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 825 employees. Market cap is $148.9B.
The current price is ₩5,330 with a P/E ratio of 17.14x and P/B of 0.39x.
ROE is 2.31% and operating margin is 0.05%. Annual revenue is $496.4B.